Join MatTek and IONTOX scientists for a webinar on how using integrated organ systems in conjunction with MatTek’s EpiIntestinal™ is being used to study cholestatic drug-induced liver injury in vitro. When: Wednesday, May 2nd at 11am EST.
Panelists:
Dr. Seyoum Ayehunie received his B.Sc. (1983) and Master’s degrees (1987) in Biology from Addis Ababa University, Ethiopia and his Ph.D. in medical microbiology from the Karolinska Institute (1992), Stockholm, Sweden, did his post-doctoral fellowship at Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA (1993-1997). Dr. Seyoum Ayehunie is currently, Vice president of Immunological Systems at MatTek Corporation. In the last four years, he has developed a new in vitro primary human cell-based organotypic small intestinal (EpiIntestinal) tissue model. The 3D-human small intestinal tissue model recapitulates the structural features and physiological barrier properties of the native human small intestine.
Dr. Jamin A. Willoughby, Sr., received his B.S. in Biology from Indiana University – South Bend in 2002 and went on to receive his Doctorate of Philosophy (Ph.D.) in Molecular and Cell Biology from the University of California, Berkeley in 2007. He is a member of the Society of Toxicology and has published numerous peer-reviewed manuscripts. Dr. Willoughby has substantial experience in assay development, in particular with three-dimensional tissue models, as well as expertise in many areas including dermal and ocular toxicity, genotoxicity, and endocrine disruption. Dr. Jamin A. Willoughby, Sr., currently serves as Vice President of Toxicology at IONTOX, LLC.
Learn more about how you can incorporate these technologies into your preclinical testing strategy:
